Fierce Pharma

Clinical trials reach a new automation inflection point

Sep 14, 2026 3:03pm

As trial complexity grows, agentic AI is emerging as a new model for connecting workflows and accelerating execution.

Eli Lilly escalates oral SERD battle with FDA approval for Inluriyo, Verzenio combo

Sep 18, 2026 2:53pm

With longer progression-free survival, Jake Van Naarden, president of Lilly Oncology, told Fierce he expects most patients to choose the combination over oral SERD monotherapy.

Europe's CHMP endorses slew of new medicines, including new offerings from Novo and AZ

Sep 18, 2026 10:39am

The CHMP recommendation for Novo's next gen hemophilia A treatment was one of several noteworthy endorsements made by the EU agency this week.

The Oral GLP-1 Tracker: Holiday takes toll on prescriptions

Apr 21, 2026 10:06am

Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts’ notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie to become the go-to oral weight-loss solution for millions.

Panthers and zebras and meerkats, oh my: A peek behind the curtain at Fierce Pharma Week 2026

Sep 18, 2026 10:44am

With many of the healthcare industry’s top marketing minds converging in the City of Brotherly Love this past week, the galvanizing power of humor, authenticity and a little outside-of-the-box thinking in an ever-changing consumer landscape was again at the forefront of Fierce Pharma Week.

Fierce Pharma Asia—China deals safe from COINS?; Key WCLC data; Legend’s new CEO

Sep 18, 2026 9:57am

Most drug licensing deals with China will be safe from rules being drafted by the U.S. Treasury Department, Reuters reports. Akeso and Summit's ivonescimab, B7-H3 ADCs and a surprise negative overall survival trend from Enhertu headlined WCLC26. Plus more.

FDA approves Ultragenyx’s gene therapy Fayuvi for rare neurodegenerative disorder

Sep 17, 2026 4:21pm

Ultragenyx scored a belated regulatory win with FDA approval for a first-in-disease gene therapy, giving the company a boost after a previous regulatory rejection and a recent late-stage setback.

Bayer’s Kerendia secures FDA nod as first drug in 30 years for Type 1 diabetes-associated kidney disease

Sep 17, 2026 1:11pm

The heart and kidney med earned the first FDA nod in three decades for adults with chronic kidney disease associated with type 1 diabetes.

Roche’s Lunsumio delivers positive confirmatory trial readout in follicular lymphoma

Sep 17, 2026 10:26am

Roche’s T-cell engager portfolio has notched another milestone, as a phase 3 trial of the company’s Lunsumio met its primary endpoint in earlier-line follicular lymphoma.

Bavarian Nordic secures Sanofi, AZ vet to fill shoes of longtime CEO Paul Chaplin

Sep 17, 2026 11:06am

Following the news that longtime helmsman Paul Chaplin would be hanging up his hat at Bavarian Nordic earlier this year, the Danish vaccine maker has found a CEO replacement whose CV spans leadership roles across Sanofi, AstraZeneca and Pfizer.

Sun Pharma shines a light on alopecia areata in ‘Regrowth Restyled’ campaign

Sep 17, 2026 9:57am

Sun Pharma is teaming up with fashion designer Christian Siriano for a new educational campaign focused on the positives of regrowing lost hair.

Eli Lilly dishes out fresh produce to cultivate Alzheimer’s awareness

Sep 17, 2026 10:14am

Eli Lilly is marking World Alzheimer’s Day with a partnership to distribute 13,500 boxes of brain-healthy fresh produce and educational materials to underserved senior populations across the U.S.

FDA drops warning letter on Bausch & Lomb, citing contamination concerns

Sep 17, 2026 7:52am

The FDA issued a warning letter to Bausch & Lomb over contamination concerns at its Tampa, Florida, facility that produces prescription and over-the-counter eye medications.

‘People like the sincerity of it’: comedian Damon Wayans on humor, relatability and DME awareness in Genentech campaign

Sep 17, 2026 9:34am

The comedian sat down with Fierce to discuss his health advocacy journey as a type 2 diabetic and his work using comedy and humor to bring light to sight-related diabetes complications in Genentech's "All Eyes on DME."

'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrand

Sep 16, 2026 9:40pm

Novo CEO Mike Doustdar—tapped to breathe new life into the Danish drugmaker last year after losing GLP-1 marketing ground to chief rival Eli Lilly—isn’t one to make changes for the sake of change.

Ex-PHM CEO Andrea Palmer takes top job at Assembled Intelligence

Sep 17, 2026 6:47am

Former Publicis Health Media CEO Andrea Palmer has revealed her next post. The executive has taken the CEO position at Assembled Intelligence, the agency that Minds + Assembly launched last year to integrate its flurry of acquisitions.

AZ, Daiichi's Enhertu scores long-awaited NICE blessing in HER2-low breast cancer

Sep 16, 2026 3:14pm

After a 2024 rebuff, AstraZeneca and Daiichi Sankyo’s star antibody drug conjugate Enhertu has been deemed cost effective for NHS use in HER2-low advanced breast cancer by England and Wales' drug value assessor.

Vera’s strong phase 3 IgAN data for Trutakna intensify kidney disease rivalry

Sep 16, 2026 2:30pm

New phase 3 data show Vera Therapeutics’ Trutakna successfully stabilizes kidney function in IgA nephropathy patients, mirroring an earlier clinical success from Otsuka’s Voyxact and heating up competition in a rapidly evolving market race.

Cellares links with GenomeFrontier to test automation approach for virus-free CAR-Ts

Sep 16, 2026 1:08pm

Cellares is partnering with Taiwanese biotech GenomeFrontier Therapeutics to evaluate the integrated contract developer and manufacturer’s cell shuttle platform for use in the production of virus-free CAR-T therapies.

Trialynx Wins DPHARM Idol Disrupt 2026

Sep 16, 2026 12:48pm

Trialynx takes home the DPHARM Idol Disrupt award from the 2026 DPHARM conference.

BMS, Ono take Amgen to task as FDA's Opdivo biosimilar decision looms

Sep 16, 2026 10:51am

As Amgen advances its bid to join the first wave of biosimilars to Bristol Myer Squibb and Ono’s oncology mega-blockbuster Opdivo, the originator drug’s partners are not taking the challenge lying down.

Reckitt allots $600 million in upgrade of its U.S. operations

Sep 16, 2026 10:00am

The health and hygiene conglomerate, known for brands like Lysol and Mucinex, will spend the funds building out an R&D hub at its new headquarters and finalizing the largest of its seven manufacturing sites by 50%.

Legend Biotech names Novartis veteran Ingrid Zhang as new CEO

Sep 16, 2026 9:51am

Legend Biotech has found its permanent CEO, poaching 15-year Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its next phase of growth.

Ori locks down $120M pact to deploy automated production platform for unnamed commercial cell therapy

Sep 16, 2026 9:05am

As a key player in the automated cell therapy manufacturing space grapples with a recent setback, another is making waves with a major commercial pact.

CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’

Sep 9, 2026 5:09pm

Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammation, CEO Daniel O’Day told Fierce.